Results 341 to 350 of about 774,384 (405)

Shared immunological pathways in rheumatoid arthritis-related interstitial lung disease. [PDF]

Front Immunol
Xu J, Li C, Zhao J, Mu R.
europepmc   +1 more source

Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease. [PDF]

Clin Respir J
Lewandowska AA, Waśniowska D, Rybacki C, Graczyk M, Duszyńska O, Mirus-Arabik H, Gaczkowska A, Kołodziej M.   +7 more
europepmc   +1 more source

Interstitial lung disease in Malta

, 2012
Caroline Gouder, M Fenech, Stephen Montefort   +2 more
openalex   +1 more source

Interstitial Lung Disease and Risk of Lung Cancer.

JAMA Netw Open
Xu H, Yin L, Bian W, Kang M, Adami HO, Ye W.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interstitial lung diseases

The Lancet, 2022
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised. Most interstitial lung diseases are characterised by inflammation or fibrosis within the interstitial space, the primary consequence of which is impaired gas exchange, resulting in breathlessness, diminished exercise tolerance, and decreased quality of life ...
Marlies, Wijsenbeek, Atsushi, Suzuki, Toby M, Maher   +2 more
openaire   +2 more sources

Drug-induced interstitial lung disease

European Respiratory Journal, 2022
Interstitial lung disease (ILD) secondary to drug-induced lung injury is an increasingly common cause of morbidity and mortality. The number of drugs associated with the development of ILD continues to rise, mainly due to the use of novel monoclonal ...
P. Spagnolo, P. Bonniaud, G. Rossi, N. Sverzellati, V. Cottin   +4 more
semanticscholar   +1 more source

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.

JAMA Oncology, 2021
Importance In the past decade, ERBB2 (formerly HER2)-directed antibody-drug conjugates (ADCs) have substantially changed treatment of both advanced and early-stage ERBB2-positive breast cancer. Novel conjugates are now showing activity in trials of other
P. Tarantino, S. Modi, S. Tolaney, J. Cortés, E. Hamilton, Sung-Bae Kim, Masazaku Toi, F. André, G. Curigliano   +8 more
semanticscholar   +1 more source